Ionis EVP Disposes $412K in Stock as Company Advances Multiple Regulatory Filings
Eugene Schneider, executive vice president and chief clinical development officer at Ionis Pharmaceuticals (IONS), sold 5,812 shares on March 19, 2026, for about $412,486 under a pre-arranged Rule 10b5-1 plan. The company is concurrently navigating several regulatory milestones, with two Priority Review target action dates in 2026 and new clinical …